德拉马尼治疗耐多药结核病的研究进展

Research Progress on Delamanid in the Treatment of Multi-drug Resistant Tuberculosis

耐多药结核病(MDR-TB)仍是目前全球公共卫生危机和卫生安全威胁之一,而我国是MDR-TB高负担国家之一。德拉马尼作为一种新型抗结核药物,主要通过抑制结核分枝杆菌细胞壁分枝菌酸合成而发挥杀菌作用,并有望缩短MDR-TB治疗疗程,已引起临床关注和重视。本文主要综述了德拉马尼的作用机制及抗菌活性、临床前研究及临床试验、毒副作用及药物-药物相互作用、耐药机制等,以提高临床对德拉马尼的认识并为合理应用该药提供参考。

Multi-drug resistant tuberculosis(MDR-TB)is one of global public health crises and threats to health security,however China is one of the countries with high burden of MDR-TB. As a new anti-tuberculosis drug,delamanid plays an antibacterial role by inhibiting the synthesis of mycolic acid in cell wall of Mycobacterium tuberculosis,which is expected to shorten the course of treatment of MDR-TB and has attracted clinical attention. This paper mainly reviewed the action mechanism and antibacterial activity,preclinical studies and clinical trials,toxic side effects and drug-drug interaction,resistance mechanism of delamanid,to improve the clinical understanding and rational usage level of delamanid.